Details of the Drug Reposition

General Information of This Drug (ID: DMWM4D0)

Drug Name
Futibatinib   DMWM4D0
Synonyms TAS-120
Structure
3D MOL 2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
1 Approved Indication(s)
Indication Name Indication ID ICD-11 Status REF
Intrahepatic cholangiocarcinoma DIS6GOC8 2C12.10 Approved [1]
------------------------------------------------------------------------------------
2 Phase 1/2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Solid tumour/cancer DISZR48F 2A00-2F9Z Phase 1/2 [2]
Multiple myeloma DISEWP9B 2A83 Phase 1/2 [3]
------------------------------------------------------------------------------------

References

1 FDA Approved Drug Products from FDA Official Website. 2022. Application Number: 214801.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 ClinicalTrials.gov (NCT02052778) A Dose Finding Study Followed by a Safety and Efficacy Study in Patients With Advanced Solid Tumors or Multiple Myeloma With FGF/FGFR-Related Abnormalities. U.S. National Institutes of Health.